Uncategorized
Ranibizumab safe long-term for neovascular age-related macular degeneration
NEW YORK (Reuters Health) - Ranibizumab injections may be safely used for at least three years in
patients with neovascular age-related macular degeneration (nAMD), according to findings from the SECURE
study.